SUPN Share Price

Open 41.05 Change Price %
High 41.90 1 Day 0.70 1.71
Low 40.51 1 Week 0.00 0.00
Close 41.60 1 Month 0.25 0.60
Volume 330025 1 Year 20.00 92.59
52 Week High 50.04
52 Week Low 20.55
SUPN Important Levels
Resistance 2 42.89
Resistance 1 42.36
Pivot 41.34
Support 1 40.84
Support 2 40.31
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

SUPN Technical Analysis 1.5
As on 31st Oct 2017 SUPN Share Price closed @ 41.60 and we RECOMMEND Buy for LONG-TERM with Stoploss of 34.70 & Sell for SHORT-TERM with Stoploss of 43.02 we also expect STOCK to react on Following IMPORTANT LEVELS.
SUPN Target for November
1st Target up-side 43.58
2nd Target up-side 44.97
3rd Target up-side 46.35
1st Target down-side 39.62
2nd Target down-side 38.23
3rd Target down-side 36.85
SUPN Other Details
Segment EQ
Market Capital 306384160.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.supernus.com
SUPN Address
SUPN
1550 East Gude Drive
Rockville, MD 20850
United States
Phone: 301-838-2500
SUPN Latest News
Interactive Technical Analysis Chart Supernus Pharmaceuticals, Inc. ( SUPN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Supernus Pharmaceuticals, Inc.
SUPN Business Profile
Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.